However, further refinement and testing is necessary before it can be widely used.
 The newly developed STRAIN-EOS, an observation-based assessment tool designed to assess stressors specifically in the healthcare sector, was shown to be potentially useful. However, further refinement and testing is necessary before it can be widely used.Previous studies revealed that experiences of stigma may negatively affect health service utilization (HSU) among young rural-to-urban migrants. Existing literature also suggested social factors including social capital may mediate such negative effect. However, data are limited regarding the mediation role of social capital among this vulnerable population. Therefore, the current study aimed to examine the associations among experiences of stigma, social capital, and HSU among young rural-to-urban migrants in China. A sample of 641 young rural-to-urban migrants was recruited through a venue-based sampling approach in Beijing, China. Participants were assessed on sociodemographic characteristics, experiences of stigma, and social capital in their urban communities. Self-reported frequency of physical examinations (regularly, irregularly, none) was used as an indicator of HSU. Structural equation modeling (SEM) was performed to examine the direct effect of stigma on HSU as well as the mediation effect of social capital. Among the 641 young rural-to-urban migrants, 32.3% (195/603) reported never having physical examinations while 50.6% (305/603) reported having them irregularly. The final model showed a goodness of fit (χ2/df=1.7, CFI=0.98, RMSEA=0.03, WRMR=0.74). Results of SEM revealed that both of the direct and indirect paths from experiences of stigma on HSU were statistically significant. There was a partial mediation effect of social capital on the association between experiences of stigma and HSU (delta z score=-5.49, p less then 0.01). Rural-to-urban migrants have a low rate of regular HSU. Experiences of stigma is associated with decreased likelihood of HSU. Social capital in the urban communities can mediate the negative effect of stigma on HSU and plays a mediation role between experiences of stigma and HSU. Therefore, to increase HSU among migrants, targeted interventions to reduce stigma and increase social capital at the migration destinations are needed.[This corrects the article DOI 10.1186/s12991-020-00261-y.].
  Diabetes mellitus is the most common metabolic disorder worldwide. We aimed to determine the metabolic and clinical responses to Bunium Persicum (Black Caraway) supplementation in overweight and obese patients with T2DM.
 
  Participant recruitment took place in the diabetic clinic of Bu-Ali hospital in Zahedan. Due to the eligibility criteria, 60 participants were randomly placed into two groups, namely placebo (
   = 30) and BP (
   = 30).  https://www.selleckchem.com/products/Eloxatin.html  The supplementation was considered one 1000 mg capsule 2 times /day BP by meals (lunch and dinner) for 8 weeks. Physical activity levels, dietary intakes, anthropometric measurements [weight, height, and waist circumference], glycemic indices [fasting blood glucose (FBG) and insulin (FBI)], blood lipids [triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)], and serum nesfatin-1 level were determined. Homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative insulin sensitivity checks index (QUICKI), and Body Mass Index (BMI) were computed.
 
  In comparison with placebo, BP significantly decreased FBG, HOMA-IR, and BMI (
  ). The differences in the FBI, QUICKI, TG, TC, LDL, HDL, WC, and Nesfatin-1 were not significant (
  ).
 
  BP supplementation improved serum glucose indices and BMI among overweight and obese T2DM patients. Further trials are needed to confirm results.
 
  Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https//irct.ir/trial/35752.
 Iranian Registry of Clinical Trials (IRCT), IRCT20181207041876N1, Registered 18/01/2019, https//irct.ir/trial/35752.The kinetics and localization of the reactions of metabolism are coordinated by the enzymes that catalyze them. These enzymes are controlled via a myriad of mechanisms including inhibition/activation by metabolites, compartmentalization, thermodynamics, and nutrient sensing-based transcriptional or post-translational regulation; all of which are influenced as a network by the activities of metabolic enzymes and have downstream potential to exert direct or indirect control over protein abundances. Considering many of these enzymes are active only when one or more vitamin cofactors are present; the availability of vitamin cofactors likely yields a systems-influence over tissue proteomes. Furthermore, vitamins may influence protein abundances as nuclear receptor agonists, antioxidants, substrates for post-translational modifications, molecular signal transducers, and regulators of electrolyte homeostasis. Herein, studies of vitamin intake are explored for their contribution to unraveling vitamin influence over protein expression. As a body of work, these studies establish vitamin intake as a regulator of protein abundance; with the most powerful demonstrations reporting regulation of proteins directly related to the vitamin of interest. However, as a whole, the field has not kept pace with advances in proteomic platforms and analytical methodologies, and has not moved to validate mechanisms of regulation or potential for clinical application.Breathing is achieved without thought despite being controlled by a complex neural network. The diaphragm is the predominant muscle responsible for force/pressure generation during breathing, but it is also involved in other non-ventilatory expulsive behaviors. This review considers alterations in diaphragm muscle fiber types and the neural control of the diaphragm across our lifespan and in various disease conditions.
  Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder in community settings. Limited information exists on its treatment with the prosecretory agents linaclotide and lubiprostone. This retrospective cohort study investigated real-world pharmacotherapy patterns of linaclotide and lubiprostone.
 
  Patients (≥18 years) with CIC who received linaclotide or lubiprostone between January 2013 and December 2015 were identified in a United States health insurance claims database. Follow-up was from the date of the earliest claim for either drug to the end of continuous enrolment or switch to the alternative agent. Patterns of pharmacotherapy, evidence of irritable bowel syndrome (IBS), and concomitant use of selective serotonin reuptake inhibitors were examined using the International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification codes and National Drug Codes.
 
  In total, 43,164 and 17,743 patients with CIC received linaclotide and lubiprostone, respectively (~80% women, mean age ~47 years).